8-K: SRx Health Secures $4.5M in Private Placement

Sentiment:

Private Placement Announcement 18 March 2026 8:52 AM

SRx Health Solutions Inc. announced a private placement raising $4.528 million through the sale of Series B convertible preferred stock and warrants, with potential for up to $8 million.

Delay expectedA 'Filing Failure' occurs if the initial Registration Statement is not filed by the Filing Deadline (30 calendar days after the Initial Closing Date).An 'Effectiveness Failure' occurs if the Registration Statement is not declared effective by the SEC by the Effectiveness Deadline (60 or 120 calendar days after the Initial Closing Date).A 'Maintenance Failure' occurs if the Registration Statement's effectiveness lapses or the prospectus is unavailable for use, or if the common stock is suspended/delisted.A 'Current Public Information Failure' occurs if the company fails to satisfy Rule 144(c)(1) or Rule 144(i)(2) requirements, preventing investors from selling under Rule 144.Each of these failures triggers a 'Registration Delay Payment' of 2% of the investor's Purchase Price on the date of failure and every 30-day anniversary until cured.

Capital raiseThe company completed an initial private placement, raising approximately $4.528 million in cash.The Securities Purchase Agreement allows for additional closings, at the option of the investors, to raise up to a total of $8.0 million.The capital raise involves the issuance of Series B convertible preferred stock and warrants to purchase common stock.

Worse than expectedThe terms of the Series B Preferred Stock and Warrants are highly dilutive to existing common shareholders, with variable conversion/exercise prices that can adjust downwards based on market performance, increasing the number of shares issued.The 15.0% per annum default dividend rate on Series B Preferred Stock is a substantial financial burden if the company experiences a 'Triggering Event'.The company faces significant penalties, including daily cash payments of 2% of the investor's purchase price, for failures such as not filing or making effective a registration statement, or not timely delivering shares.The company's optional redemption of Series B Preferred Stock at 125% of the conversion amount or market value represents a high premium, making future redemptions costly.The transaction includes notable non-accountable fees to the lead buyer's counsel ($75,000 at initial closing, $50,000 at each additional closing), which are borne by the company.

Summary

SRx Health Solutions Inc. (SRXH) entered into a Securities Purchase Agreement on March 16, 2026, with certain accredited investors for a private placement.
At the initial closing on March 16, 2026, the company issued and sold 5,660 shares of Series B convertible preferred stock and 22,237,666 warrants to purchase common stock, generating approximately $4.528 million in cash proceeds.
The private placement allows for additional closings, at the investors' option, to raise up to an aggregate of $8.0 million.
Each share of Series B Preferred Stock has a stated value of $1,000 and ranks senior to common stock, pari passu with Series A preferred stock, regarding dividends and liquidation.
The warrants have an initial exercise price of $0.3182 and expire on the third anniversary of their initial exercisability date.
Both the Series B Preferred Stock and Warrants have an initial conversion/exercise price of $0.3182, subject to various adjustments, including downward adjustments based on market prices after stockholder approval.
The company is required to seek stockholder approval for the issuance of all common stock underlying the Series B Preferred Stock and Warrants, in compliance with NYSE American rules.
Holders of Series B Preferred Stock are entitled to dividends on an as-if converted basis, and a 15.0% per annum default dividend accrues if a 'Triggering Event' occurs.
The company can optionally redeem all outstanding Series B Preferred Stock at 125% of the greater of the conversion amount or a market-based value.
A Registration Rights Agreement was also executed, obligating the company to register the common stock underlying the Series B Preferred Stock and Warrants for resale.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly dilutive financing event with aggressive terms favoring investors, indicating potential financial strain or a significant need for capital. The high penalties for company non-compliance and the variable pricing mechanisms could significantly impact existing shareholder value.

Positives

Secured $4.528 million in cash at the initial closing, providing capital for general corporate purposes.
Potential to raise up to an additional $3.472 million, bringing the total capital raise to $8.0 million, at the investors' option.
The financing structure provides investors with strong anti-dilution protections and favorable conversion/redemption terms.

Negatives

The terms of the Series B Preferred Stock and Warrants are highly dilutive to existing common shareholders, particularly due to variable conversion/exercise prices and aggressive anti-dilution provisions.
A high default dividend rate of 15.0% per annum accrues on the Series B Preferred Stock if a 'Triggering Event' occurs, increasing the company's financial burden.
The company faces strict covenants and potential penalties for non-compliance, including daily cash payments for failure to timely deliver shares or maintain registration effectiveness.
The company's optional redemption price for Series B Preferred Stock is set at a significant premium of 125% of the conversion amount or market value, which is costly.
Significant transaction expenses, including $75,000 at the initial closing and $50,000 at each additional closing, are payable to the lead buyer's counsel.

Risks

Failure to obtain stockholder approval for the issuance of common stock underlying the Series B Preferred Stock and Warrants could lead to further penalties or limitations.
Risk of delisting or suspension of common stock from the Principal Market (NYSE American) if the company fails to meet listing requirements or maintain current public information.
Insufficient authorized shares of common stock to satisfy conversion or exercise obligations could result in cash payments to holders at potentially unfavorable market prices.
The company's failure to timely deliver shares upon conversion or exercise, or to maintain an effective registration statement, triggers daily cash penalties to investors.
The company is subject to numerous covenants, including restrictions on incurring indebtedness, creating liens, making restricted payments, changing the nature of its business, and issuing certain other securities without investor consent.
A 'Triggering Event' (e.g., registration statement failures, trading suspension, payment defaults, bankruptcy) can lead to mandatory redemption of preferred shares at a premium or trigger alternate conversion rights at discounted market prices.

Future Outlook

The company is obligated to seek stockholder approval for the issuance of all common stock underlying the Series B Preferred Stock and Warrants, and to file a registration statement for their resale. It also has the potential to raise additional capital up to $8.0 million through further closings at the investors' discretion. The company must maintain its listing on the NYSE American and comply with various covenants to avoid triggering events and associated penalties.

Management Comments

Carolina Martinez, Chief Financial Officer, Secretary and Treasurer, signed the Form 8-K and Certificate of Designations on behalf of SRx Health Solutions Inc.

Industry Context

StockSavvy.ai notes this private placement is a common strategy for growth-stage companies to raise capital. However, the terms, particularly the aggressive anti-dilution and variable pricing mechanisms, along with high default penalties, are notably investor-favorable. This structure often indicates a challenging fundraising environment for the company or a significant need for capital, where the company must concede substantial future equity value to secure immediate funding.

Comparison to Industry Standards

The 15.0% default dividend rate on Series B preferred stock is significantly higher than typical preferred stock offerings, which commonly range from 5-10% for established companies.
The 125% company optional redemption premium is also above average, as typical premiums for preferred stock redemptions are often in the 105-115% range.
The variable conversion/exercise prices and strong anti-dilution provisions, which can adjust downwards based on market price, are aggressive and more commonly seen in financings for micro-cap or distressed companies, rather than those with strong market positions like large-cap industry leaders.
The strict penalties for company non-compliance, such as the 2% daily cash payment for delivery or registration failures, are more severe than standard market terms and place a heavy burden on the company.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
New Class of Preferred Stock	Creation and establishment of Series B Convertible Preferred Stock with specific rights, preferences, and limitations, including a $1,000 stated value and senior ranking to common stock.	2026-03-10	Introduces a new class of equity with significant preferential rights, potentially impacting common shareholders' claims on assets and earnings.
Stockholder Approval Requirement	Requirement to obtain stockholder approval for the issuance of all common stock underlying the Series B Preferred Stock and Warrants, in compliance with NYSE American rules.	2026-03-16	Ensures shareholder oversight on significant dilution, but failure to obtain approval could trigger penalties or limit the company's ability to fulfill obligations.
Covenants and Restrictions	Imposition of various covenants restricting the company's ability to incur certain indebtedness, create liens, make restricted payments or cash dividends, transfer assets outside the ordinary course, change business nature, or issue certain other securities without 'Required Holders' consent.	2026-03-16	Limits management's operational and financial flexibility, potentially hindering future strategic initiatives or capital allocation decisions without investor approval.
Dispute Resolution Mechanism	Establishment of a dispute resolution process involving an independent investment bank for disagreements related to valuation metrics (e.g., conversion price, VWAP, redemption price).	2026-03-16	Provides a structured, independent mechanism for resolving complex valuation disputes, aiming for fairness but potentially adding time and cost.

Legal Proceedings

A 'Triggering Event' includes final judgments for the payment of money aggregating in excess of $500,000 against the company or any applicable subsidiary, if not bonded, discharged, settled, or stayed pending appeal within 30 days.

Stakeholder Impact

**Shareholders**: Existing common shareholders face significant potential dilution from the conversion of Series B Preferred Stock and exercise of Warrants, especially given the variable pricing mechanisms and anti-dilution adjustments. Their voting power could also be diluted upon conversion of these securities.
**Investors (Buyers)**: The accredited investors benefit from highly favorable terms, including strong anti-dilution protections, a high default dividend rate (15%), and a substantial redemption premium (125%), providing significant downside protection and upside potential.
**Company**: Receives needed capital for general corporate purposes but is subject to stringent covenants, potential financial penalties for non-compliance, and substantial future obligations related to share registration and reservation, which could constrain operational and financial flexibility.
**Creditors**: The Series B Preferred Stock ranks senior to common stock in liquidation, potentially impacting the recovery of unsecured creditors in a bankruptcy scenario, though it ranks pari passu with Series A Preferred Stock.

Next Steps

The company must seek stockholder approval for the issuance of all common stock underlying the Series B Preferred Stock and Warrants.
The company is required to file a registration statement with the SEC to register for resale the common stock issuable upon conversion of Series B Preferred Stock and exercise of Warrants.
The company may conduct additional closings to raise up to the remaining $3.472 million of the total $8.0 million private placement.
The company must maintain its common stock listing on the NYSE American or another Eligible Market.
The company must comply with various covenants, including maintaining sufficient authorized shares and timely SEC filings, to avoid triggering events and associated penalties.

Key Dates

Date	Description
2026-03-10	Board of Directors adopted the resolution to create Series B Convertible Preferred Stock.
2026-03-16	Issuance Date of Warrant, Subscription Date of Securities Purchase Agreement, and Initial Closing Date of the Private Placement.
2026-03-18	Date of the 8-K filing.
2026-04-15	Filing Deadline for the initial Registration Statement (30 calendar days after Initial Closing Date).
2026-05-15	Effectiveness Deadline for the initial Registration Statement (60 calendar days after Initial Closing Date, or 120 days if subject to full SEC review).
2026-12-16	Additional Closing Expiration Date (9-month anniversary of Initial Closing Date), after which buyers lose the right to effect additional closings.
2028-03-16	If any Preferred Shares remain outstanding on or after this date, it constitutes a Triggering Event.
3rd anniversary of Initial Exercisability Date	Warrant Expiration Date.

Recommendation

strong sell

The terms of this private placement are highly unfavorable to existing common shareholders, featuring significant potential for dilution through convertible preferred stock and warrants with aggressive anti-dilution and variable pricing mechanisms. The high default dividend rate (15%) and substantial redemption premium (125%) for the Series B preferred stock, coupled with strict covenants and penalties for the company, indicate a financing structure that heavily favors the new investors at the expense of current equity holders. This suggests a distressed capital need or a very weak negotiating position for SRx Health Solutions, making the common stock a strong sell.

Keywords

Private Placement, Convertible Preferred Stock, Warrants, Equity Financing, Dilution, SEC Filing, SRx Health Solutions, Corporate Governance, NYSE American, Anti-Dilution

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.